دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The dark side of arrhythmia treatment: iatrogenic tricuspid regurgitation and drug toxicity
Filippo Crea
doi : 10.1093/eurheartj/ehae026
Volume 45, Issue 5, 1 February 2024
ChatGPT hallucinating: can it get any more humanlike?
Konstantinos C. Siontis , Zachi I. Attia, Samuel J. Asirvatham, and Paul A. Friedman
Alternatives to animal experimentation in cardiovascular research: human models of disease and biobanking
Inês Falc?o-Pires
Transcatheter valvular interventions 2022: insights from the National Societies of Cardiology Journals of the European Society of Cardiology
Jean-Jacques Monsuez *1, Plamen Gatzov2, and Fernando Alfonso 3; on behalf of the Editors’ Network of the National Societies of Cardiology Journals, European Society of Cardiology
Edoxaban for atrial high-rate episodes: more harm than good?
Giovanna Liuzzo 1,2* and Carlo Patrono
Artificial intelligence: revolutionizing cardiology with large language models
Machteld J. Boonstra 1, Davy Weissenbacher 2, Jason H. Moore 2, Graciela Gonzalez-Hernandez 2, and Folkert W. Asselbergs
Tricuspid valve disease and cardiac implantable electronic devices
Martin Andreas 1*, Haran Burri 2, Fabien Praz 3, Osama Soliman4, Luigi Badano5,6, Manuel Barreiro7, Jo?o L. Cavalcante8, Tom de Potter9, Torsten Doenst10, Kai Friedrichs11, J?rg Hausleiter12,13, Nicole Karam14, Susheel Kodali15, Azeem Latib16, Eloi Marijon17, Suneet Mittal 18, Georg Nickenig19, Aldo Rinaldi 20, Piotr Rudzinski21, Marco Russo 22, Christoph Starck23, Ralph Stephan von Bardeleben24, Nina Wunderlich25, José Luis Zamorano26, Rebecca T. Hahn15, Francesco Maisano27, and Christophe Leclercq
New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry
Alexandre Gautier 1,2†, Fabien Picard 2,3†, Gregory Ducrocq 1,2, Yedid Elbez4, Kim M. Fox5, Roberto Ferrari6, Ian Ford 7, Jean-Claude Tardif 8, Michal Tendera9, and Philippe Gabriel Steg 1,2,10*; on behalf of the CLARIFY investigators
Atrial fibrillation in chronic coronary syndromes: a neglected challenge
Robert Hatala * and Peter Hliv?k
Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study
Gal Tsaban 1,2*†, Daniel Ostrovsky2,3†, Hilmi Alnsasra 1,2†, Nitzan Burrack2,3, Michal Gordon3, Amit Shira Babayev3, Yara Omari2, Louise Kezerle1,2, David Shamia1,2, Sergey Bereza1,2, Yuval Konstantino 1,2, and Moti Haim
Amiodarone for atrial fibrillation: a dead man walking?
Rui Providencia 1,2*, Kishore Kukendra-Rajah1,2, and Sergio Barra
Ventricular arrhythmias during ST-segment elevation myocardial infarction and arrhythmic complications during recurrent ischaemic events
Marina M. Demidova *, Fredrik Holmqvist , David Erlinge , and Pyotr G. Platonov
Atrial fibrillation first detected after stroke: is timing and detection intensity relevant for stroke risk?
Luciano A. Sposato 1,2,3,4,5, Gregory Y. H. Lip 6,7, and Karl Georg Haeusler
Microvascular resistance reserve, does one size fit all?
Tijn P.J. Jansen *, Caïa Crooijmans, and Peter Damman
The microvascular resistance reserve: one size fits all, but mostly one
Coen K.M. Boerhout 1*, Jan J. Piek1, and Tim P. van de Hoef
Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach
Leonhard Wert 1*, Volkmar Falk 1,2,3,4, and Evgenij V. Potapov
Myocardial infarction caused by in situ thrombosis of a patent foramen ovale assessed by optical coherence tomography
Wenhao Liu†, Beibei Song†, and Bo Li
Correction to: Fulminant myocarditis proven by early biopsy and outcomes
Correction to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
